RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CMV strategy aims to protect stem cell transplant patients from dangerous infection
Disease control OngoingThis study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…
Matched conditions: RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Experimental combo targets Hard-to-Treat lymphoma
Disease control OngoingThis study tests a drug called durvalumab, given alone or with lenalidomide, in people with T-cell lymphoma that returned or didn't respond to prior treatments. The goal is to find the best dose, check safety, and see if the combination shrinks tumors. About 38 adults with certai…
Matched conditions: RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC